- Amendments to the Claims -

Amend claims 1, 4, 7, 9, 12, 13, 14, 17, 20, 21, 23 and 25; cancel claims 2, 3, 5, 6, 8, 24 and 26 - 30; and add new claims 31 - 40 as follows:

1. (Currently amended) A compound of Formula (1.0.0):



(1.0.0)

— wherein —

-j is ~~0 or~~ 1; ~~provided that when j is 0, n must be 2;~~

-k is 0 or 1

-m is 1, 2, or 3;

-n is 1 or 2;

-W^1 and W^2 are independently —O— ; or —$S(=O)_t$— , where t is 0, 1, or 2; ~~or -N(R^3) where R^3 has the same meaning as defined below;~~

-Y is =C($R^1{}_a$)—, where $R^1{}_a$ has the same meaning as defined below; ~~or -[N=>$(O)_k$]— where k is 0 or 1;~~

— where —

--$R^1{}_a$ is a member selected from the group consisting of –H; –F; –Cl; –CN; –NO_2; –(C_1-C_4) alkyl; –(C_2-C_4) alkynyl; fluorinated–(C_1 -C_3) alkyl; fluorinated-(C_1 -C_3) alkoxy; -OR^{16}; and –C(=O)$NR^{22}{}_aR^{22}{}_b$;

— where —

---$R^{22}{}_a$ and $R^{22}{}_b$ are each independently –H; –CH_3; –CH_2CH_3; –$CH_2CH_2CH_3$; -$CH_2(CH_3)_2$; –$CH_2CH_2CH_2CH_3$; –$CH(CH_3)CH_2CH_3$; –$CH_2CH(CH_3)_2$; –$C(CH_3)_3$; cyclopropyl; cyclobutyl; or cyclopentyl;

-R^A and R^B are each a member independently selected from the group consisting of –H; –F; –CF_3; –(C_1-C_4) alkyl; –(C_3-C_7) cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents R^{10};

— where —

--R^{10} is a member selected from the group consisting of phenyl; pyridyl; –F; -Cl; -CF_3; oxo (=O); –OR^{16}; –NO_2; –CN; –$C(=O)OR^{16}$; -O-$C(=O)R^{16}$; –$C(=O)NR^{16}R^{17}$; -O-$C(=O)NR^{16}R^{17}$; –$NR^{16}R^{17}$; –$NR^{16}C(=O)R^{17}$; -$NR^{16}C(=O)OR^{17}$; –$NR^{16}S(=O)_2R^{17}$; and -$S(=O)_2NR^{16}R^{17}$; where said phenyl or pyridyl is substituted by 0 to 3 R^{11};

— where —

---R^{11} is –F; –Cl; –CF_3; –CN; –NO_2; –OH; –(C_1-C_3) alkoxy; –(C_1-C_3) alkyl; or -$NR^{16}R^{17}$;

— and —

----R^{16} and R^{17} are each a member independently selected from the group consisting of –H; –(C_1-C_4) alkyl; –(C_2-C_4) alkenyl; –(C_3-C_6) cycloalkyl; phenyl; benzyl; and pyridyl; wherein said alkyl, alkenyl, cycloalkyl, phenyl, benzyl, or pyridyl is substituted by 0 to 3 substituents selected from the group consisting of –F, –Cl, –CF_3, –CN, and –(C_1-C_3) alkyl;

~~— or —~~

~~-R^A and R^B are taken together, but only in the case where m is 1, to form a spiro moiety of Formula (1.2.0):~~



~~(1.2.0)~~

~~— where —~~

~~--r and s are independently 0 to 4 provided that the sum of r + s is at least 1 but not greater than 5;~~

~~— and —~~

~~--X^A is selected from –CH_2–, –$CH(R^{11})$–, or –$C(R^{11})_2$–, where each R^{11} is selected independently of the other and each has the same meaning as defined above; –NR^{15}–, where R^{15} has the same meaning as defined below; –O–; and –$S(=O)_t$–, where t is 0, 1, or 2;~~

~~— and —~~

~~said spiro moiety of partial Formula (1.2.0) is substituted as to any one or more carbon atoms thereof, other than that defining X^A, by 0 to 3 substituents R^{14}, where R^{14} has the same meaning as defined below; as to a nitrogen atom thereof by 0 or 1 substituent R^{15}, where R^{15} has the same meaning as defined below; and as to a sulfur atom thereof by 0 or 2 oxygen atoms;~~

-R^C and R^D have the same meaning as defined above for R^A and R^B except that one of them must be –H, and they are selected independently of each other and of R^A and R^B;

-R^1 and R^2 may individually or together appear on any ring or rings comprising a meaning of the moiety J^2 as defined below; and R^1 and R^2 are each a member independently selected from the group consisting of –H; –F; –Cl; –CN; $–NO_2$; $–(C_1\text{-}C_4)$ alkyl; $–(C_2\text{-}C_4)$ alkynyl; fluorinated–$(C_1\text{-}C_3)$ alkyl; $–OR^{16}$; and $\text{-C(=O)NR}^{22}{}_a\text{R}^{22}{}_b$; where R^{16}, $R^{22}{}_a$, and $R^{22}{}_b$ have the same meanings as defined above;

-R^3 is –H; $–(C_1\text{-}C_3)$ alkyl; phenyl; benzyl; or $–OR^{16}$, where R^{16} has the same meaning as defined above;

-R^4~~, R^5 and R^6~~ may ~~individually or together~~ appear on any ring or rings comprising a meaning of the moiety J^1 as defined below; and R^4~~, R^5 and R^6~~ are each a member independently selected from the group consisting of

— the following: —

-*(a)* –H; –F; –Cl; $\text{-(C}_2\text{-C}_4\text{)}$ alkynyl; -R^{16}; $–OR^{16}$; $–S(=O)_pR^{16}$; $–C(=O)R^{16}$; -C(=O)OR^{16}; $–OC(=O)R^{16}$; –CN; $-NO_2$; $\text{-C(=O)NR}^{16}\text{R}^{17}$; $–OC(=O)NR^{16}R^{17}$; $–NR^{22}{}_aC(=O)NR^{16}R^{17}$; $\text{-NR}^{22}{}_a\text{C(=NR}^{12}\text{)NR}^{16}\text{R}^{17}$; $\text{-NR}^{22}{}_a\text{C(=NCN)NR}^{16}\text{R}^{17}$; $\text{-NR}^{22}{}_a\text{C(=N-NO}_2\text{)NR}^{16}\text{R}^{17}$; $\text{-C(=NR}^{22}{}_a\text{)NR}^{16}\text{R}^{17}$; $\text{-CH}_2\text{C(=NR}^{22}{}_a\text{)NR}^{16}\text{R}^{17}$; $–OC(=NR^{22}{}_a)NR^{16}R^{17}$; $–OC(=N–NO_2)NR^{16}R^{17}$; $\text{-NR}^{16}\text{R}^{17}$; $\text{-CH}_2\text{NR}^{16}\text{R}^{17}$; $\text{-NR}^{22}{}_a\text{C(=O)R}^{16}$; $\text{-NR}^{22}{}_a\text{C(=O)OR}^{16}$; $=NOR^{16}$; $–NR^{22}{}_aS(=O)_pR^{17}$ $\text{-S(=O)}_p\text{NR}^{16}\text{R}^{17}$; and $\text{–CH}_2\text{C(=NR}^{22}{}_a\text{)NR}^{16}\text{R}^{17}$;

— where —

--p is 0, 1, or 2; and $R^{22}{}_a$, R^{16}, and R^{17} have the same meanings as defined above;

-*(b)* $\text{-(C}_1\text{-C}_4\text{)}$ alkyl; and $–(C_1\text{-}C_4)$ alkoxy in the case where ~~one or more of~~ R^4~~, R^5, or R^6~~ has the meaning of -OR^{16} under *(a)* above and R^{16} is defined as $\text{-(C}_1\text{-C}_4\text{)}$ alkyl; wherein said alkyl and alkoxy are each independently substituted with 0 to 3 substituents –F or –Cl; or 0 or 1 substituent $(C_1\text{-}C_2)$ alkoxycarbonyl–; $(C_1\text{-}C_2)$ alkylcarbonyl–; or $(C_1\text{-}C_2)$ alkylcarbonyloxy–; provided R^{16} and R^{17} in the definition of R^4 is not pyridyl;

— and —

-*(c)* ~~an aryl or heterocyclyl moiety selected from the group consisting of~~ phenyl~~;~~ or benzyl; ~~furanyl; tetrahydrofuranyl; oxetanyl; thienyl; tetrahydrothienyl; pyrrolyl; pyrrolidinyl; oxazolyl; oxazolidinyl; isoxazolyl; isoxazolidinyl; thiazolyl; thiazolidinyl; isothiazolyl; isothiazolidinyl; pyrazolyl; pyrazolidinyl; oxadiazolyl; thiadiazolyl; imidazolyl; imidazolidinyl; pyridinyl; pyrazinyl; pyrimidinyl; pyridazinyl; piperidinyl; piperazinyl; triazolyl; triazinyl; tetrazolyl; pyranyl; azetidinyl; morpholinyl, parathiazinyl; indolyl; indolinyl; benzo[*b*]furanyl; 2,3-dihydrobenzofuranyl; 2-*H*-chromenyl; chromanyl; benzothienyl; 1-*H*-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzthiazolyl; quinolinyl; isoquinolinyl; phthalazinyl; quinazolinyl; quinoxalinyl; and purinyl; wherein said aryl and heterocyclyl moieties are each independently substituted with 0 to 2 substituents R^{14}~~

~~—where—~~

--R^{14} is a member selected from the group consisting of $-(C_1-C_4)$ alkyl; $-(C_3-C_7)$ cycloalkyl; phenyl; benzyl; ~~pyridyl; and quinolinyl;~~ where said alkyl, cycloalkyl, phenyl~~,~~ and benzyl~~, pyridyl, or quinolinyl is~~ are substituted by 0, 1, or 2 substituents –F, –Cl, $-CH_3$, $-OR^{16}$, $-NO_2$, –CN, or $-NR^{16}R^{17}$; and said R^{14} group further consists of –F; -Cl; $-CF_3$; oxo (=O); $-OR^{16}$; $-NO_2$; –CN; $-C(=O)OR^{16}$; $-O-C(=O)R^{16}$; $-C(=O)NR^{16}R^{17}$; $-O-C(=O)NR^{16}R^{17}$; $-NR^{16}R^{17}$; $-NR^{16}C(=O)R^{17}$; $-NR^{16}C(=O)OR^{17}$; $-NR^{16}S(=O)_2R^{17}$; or $-S(=O)_2NR^{16}R^{17}$; where R^{16} and R^{17} have the same meanings as defined above; provided that said R^{16} and R^{17} in the definition of R^{14} is not pyridyl;

~~—and further where—~~

~~--R^{15} is a member independently selected from the group consisting of –H; $-NR^{16}R^{17}$; $-C(=O)R^{16}$; $-OR^{16}$; $-(C_1-C_4)$ alkyl-OR^{16}; $-C(=O)OR^{16}$; $-(C_1-C_2)$ alkyl-$C(=O)OR^{16}$; $-C(=O)NR^{16}R^{17}$; $-(C_1-C_4)$ alkyl; $-(C_2-C_4)$ alkenyl; $-(CH_2)_u-(C_3-C_7)$ cycloalkyl where u is 0, 1 or 2; phenyl; benzyl; pyridyl; and quinolinyl; wherein said alkyl, alkenyl, alkoxy, cycloalkyl, phenyl, benzyl, pyridyl or quinolinyl is substituted with 0 to 3 substituents R^{12}; where R^{16} and R^{17} have the same meanings as defined above; and~~

~~—where—~~

----R^{12} is a member independently selected from the group consisting of –F; –Cl; $-CO_2R^{18}$; $-OR^{16}$; –CN; $-C(=O)NR^{18}R^{19}$; $-NR^{18}R^{19}$; $-NR^{18}C(=O)R^{19}$; $-NR^{18}C(=O)OR^{19}$; $-NR^{18}S(=O)_pR^{19}$; $-S(=O)_pNR^{18}R^{19}$, where p is 1 or 2; $-(C_1-C_4)$ alkyl; and $-(C_1-C_4)$ alkoxy in the case where R^{12} has the meaning of $-OR^{16}$ above and R^{16} is defined as $-(C_1-C_4)$ alkyl; wherein said alkyl and alkoxy are each independently substituted with 0 to 3 substituents independently selected from –F; –Cl; $-(C_1-C_2)$ alkoxycarbonyl; $-(C_1-C_2)$ alkylcarbonyl; and $-(C_1-C_2)$ alkylcarbonyloxy; where R^{16} has the same meaning as defined above; and

— where —

-----R^{18} and R^{19} are independently selected from the group consisting of –H; $-(C_1-C_4)$ alkyl; and phenyl; where said alkyl or phenyl is substituted by 0-3 of –F; or –Cl;

— or in the case where J' is phenyl —

-(d) R^5 and R^6 are taken together to form a moiety which is a member selected from the group consisting of partial Formulas (1.3.1) through (1.3.3) and (1.3.5) through (1.3.15):



(1.3.1) (1.3.2) (1.3.3) ~~(1.3.4)~~ (1.3.5)



(1.3.6) (1.3.7) (1.3.8) (1.3.9) (1.3.10)



(1.3.11) (1.3.12) (1.3.13) (1.3.14) (1.3.15)

— wherein —

--R^{20} and R^{21} are each a member independently selected from the group consisting of –H; –F; –Cl; $-CH_3$; $-CH_2F$; $-CHF_2$; $-CF_3$; $-OCH_3$; and $-OCF_3$;

--R^{23} and R^{24} are each independently –H; $-CH_3$; $-OCH_3$; $-CH_2CH_3$; $-OCH_2CH_3$; $-CH_2CH_2CH_3$; $-CH_2(CH_3)_2$; $-CH_2CH_2CH_2CH_3$; $-CH(CH_3)CH_2CH_3$; $-CH_2CH(CH_3)_2$; $-C(CH_3)_3$; or absent, in which case the dashed line – – – represents a double bond;

-J[1] is a moiety comprising a saturated or unsaturated carbon ring system that is a ~~3- to 7-membered~~ 6-membered monocyclic ring~~, or that is a 7- to 12-membered, fused polycyclic; provided that J[1] is not a discontinuous or restricted biaryl moiety as defined under J[3] below; and wherein optionally one carbon atom of said carbon ring system may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N;~~

~~— wherein —~~

~~said moiety defining J[1] is substituted on any ring or rings thereof by R^4, R^5 and R^6, which have the same meaning as defined above~~;

-J[2] is a moiety comprising a saturated or unsaturated carbon ring system that is a ~~3- to 7-membered~~ 6-membered monocyclic ring~~, or that is a 7- to 12-membered, fused polycyclic; provided that J[3] is not a discontinuous or restricted biaryl moiety; and wherein optionally one carbon atom of said carbon ring system may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N;~~

~~— wherein —~~

~~said moiety defining J[2] is substituted on any ring or rings thereof by R^1 and R^2, which have the same meaning as defined above~~;

-D is a member independently selected from the group consisting of

— the following —

-*(a)* the group consisting of partial Formulas (1.1.1) through (1.1.5) ~~(1.1.9)~~:



(1.1.1) (1.1.2) (1.1.3) (1.1.4)



(1.1.5) ~~(1.1.6) (1.1.7) (1.1.8) (1.1.9)~~

— wherein —

--"*" indicates the point of attachment of each partial Formula (1.1.1) through (1.1.5) ~~(1.1.9)~~ to the remaining portion of Formula (1.0.0);

--q is 1, 2, or 3, provided that where q is 2 or 3, R^9 has the meaning of –H in at least one instance, or two instances, respectively;

--v 0 or 1;

--W^3 is —O—; —N(R^9)—, where R^9 has the same meaning as defined below; or —OC(=O)—;

--R^7 is a member independently selected from the group consisting of

— the following: —

--*(1)* –H;

--*(2)* –(C_1-C_6) alkyl; –(C_2-C_6) alkenyl; or –(C_2-C_6) alkynyl; where said alkyl, alkenyl or alkynyl is substituted by 0 to 3 substituents R^{10}, where R^{10} has the same meaning as defined above; provided that R^{10} in the meaning of R^7 --(2) is not pyridyl;

--*(3)* –(CH_2)$_u$-(C_3-C_7) cycloalkyl where u is 0, 1 or 2; and further where said (C_3-C_7) cycloalkyl is substituted by 0 to 3 substituents R^{10} where R^{10} has the same meaning as defined above; provided that R^{10} in the meaning of R^7 --(3) is not pyridyl;

— and —

--*(4)* phenyl or benzyl, where said phenyl or benzyl is independently substituted by 0 to 3 substituents R^{10} where R^{10} has the same meaning as defined above; provided that R^{10} in the meaning of R^7 --(4) is not pyridyl;

--R^8 is ~~a member independently selected from the group consisting of~~

~~— the following: —~~

~~--*(1)* phenyl; tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl;~~

~~— and —~~

~~--*(2)* indolyl; indolinyl; isoindolinyl; benzo[*b*]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2*H*-1-benzopyranyl; 2-*H*-chromenyl; chromanyl; benzothienyl; 1*H*-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-*d*]pyrimidinyl; pyrimido[4,5-*d*]pyrimidinyl; imidazo[1,2-*a*]pyridinyl; pyridopyridinyl; pteridinyl; and 1*H*-purinyl;~~

— where —

said phenyl is ~~any moiety recited in *(1)* or *(2)* above is optionally substituted with respect to *(i)* any one or more carbon atoms thereof~~ optionally by a substituent R^{14} ~~where R^{14} has the same meaning as defined above; *(ii)* any one or more nitrogen atoms thereof that is not a point of attachment of said moiety, optionally by a substituent R^{15} where R^{15} has the same meaning as defined above, and all tautomer forms thereof; and *(iii)* any sulfur atom thereof that is not a point of attachment of said moiety, by 0, 1, or 2 oxygen atoms;~~

--R^9 is a member selected from the group consisting of –H; –(C_1-C_4) alkyl; -(C_3-C_7) cycloalkyl; phenyl; benzyl; ~~pyridyl;~~ –C(=O)OR^{16}; –C(=O)R^{16}; –OR^{16}; –(C_1-C_2) alkyl–OR^{16}; and –(C_1-C_2) alkyl–C(=O)OR^{16}; provided that R^{16} in the definition of R^9 is not pyridyl; ~~where R^{16} has the same meaning as defined above;~~

— and D is further selected from —

-*(b)* a moiety comprising a member selected from the group consisting of -O-P(=O)$(OH)_2$ (phosphoric); –PH(=O)OH (phosphinic); -P(=O)$(OH)_2$ (phosphonic); -[P(=O)(OH)–O(C_1-C_4) alkyl] (alkylphosphono); -P(=O)(OH)-O(C_1-C_4) alkyl) (alkylphosphinyl); –P(=O)$(OH)NH_2$ (phosphoramido); -P(=O)(OH)NH(C_1-C_4) alkyl and -P(=O)(OH)NHR^{25} (substituted phosphoramido); -O-S(=O)$_2$OH (sulfuric); –S(=O)$_2$OH (sulfonic); –S(=O)$_2$$NHR^{26}$ or

$-NHS(=O)_2R^{26}$ (sulfonamido) where R^{26} is $-CH_3$, $-CF_3$, or *o*-toluyl; and acylsulfonamido selected from the group consisting of $-C(=O)NHS(=O)_2R^{25}$; $-C(=O)NHS(=O)_2NH_2$; $-C(=O)NHS(=O)_2(C_1\text{-}C_4)$ alkyl; $-C(=O)NHS(=O)_2NH(C_1\text{-}C_4)$ alkyl; $-C(=O)NHS(=O)_2N[(C_1\text{-}C_4)\ alkyl]_2$; $-S(=O)_2NHC(=O)(C_1\text{-}C_4)$ alkyl; $-S(=O)_2NHC(=O)NH_2$; $-S(=O)_2NHC(=O)NH(C_1\text{-}C_4)$ alkyl; $-S(=O)_2NHC(=O)N[(C_1\text{-}C_4)\ alkyl]_2$; $-S(=O)_2NHC(=O)R^{25}$; $-S(=O)_2NHCN$; $-S(=O)_2NHC(=S)NH_2$; $-S(=O)_2NHC(=S)NH(C_1\text{-}C_4)$ alkyl; $-S(=O)_2NHC(=S)N[(C_1\text{-}C_4)\ alkyl]_2$; and $-S(=O)_2NHS(=O)_2R^{25}$;

— where —

$--R^{25}$ is –H; $-(C_1\text{-}C_4)$ alkyl; phenyl; or $-OR^{18}$, where R^{18} has the same meaning as defined above;

— or —

a pharmaceutically acceptable salt thereof.

2. (Canceled)

3. (Canceled)

4. (Currently amended) A compound according to Claim 1 wherein the right-hand terminus thereof, where m is 1, is represented by partial Formula (1.0.5):



(1.0.5)

where " * " is a symbol representing the point of attachment of the moiety of partial Formula (1.0.5) to the remaining portion of a compound of Formula (1.0.0); where R^A and R^B are both -H, or one is –H and the other is $-CH_3$, or both are ~~$-CH_3$, or both are taken together to form spiro-cyclopropyl or spiro-cyclobutyl~~; R^1 is –H, $-OCH_3$, or 2'–F; R^2 is -H; and the moieties J^2 and D are selected such that, said moiety of partial Formula (1.0.5) is a member selected from the group consisting of partial Formulas (1.5.1), (1.5.3), (1.5.5) through (1.5.8), (1.5.10) through (1.5.12), (1.5.17 through (1.5.22), (1.5.26), (1.5.27) and (1.5.32) ~~through (1.5.54)~~:



(1.5.1)



~~(1.5.2)~~



(1.5.3)



~~(1.5.4)~~



(1.5.5)



(1.5.6)



(1.5.7)



(1.5.8)



~~(1.5.9)~~



(1.5.10)



(1.5.11)



(1.5.12)



~~(1.5.13)~~



~~(1.5.14)~~



~~(1.5.15)~~



~~(1.5.16)~~



(1.5.17)



(1.5.18)



(1.5.19)



(1.5.20)



(1.5.21)



(1.5.22)



(1.5.23)



(1.5.24)



~~(1.5.25)~~



(1.5.26)



(1.5.27)



(1.5.28)



(1.5.29)



~~(1.5.30)~~



~~(1.5.31)~~



(1.5.32)



~~(1.5.33)~~



~~(1.5.34)~~



~~(1.5.35)~~



~~(1.5.36)~~



~~(1.5.37)~~



~~(1.5.38)~~



~~(1.5.39)~~



~~(1.5.40)~~



~~(1.5.41)~~



~~(1.5.42)~~



~~(1.5.43)~~



~~(1.5.44)~~



(1.5.45)



~~(1.5.46)~~



~~(1.5.47)~~



~~(1.5.48)~~



~~(1.5.49)~~



~~(1.5.50)~~



~~(1.5.51)~~



~~(1.5.52)~~



~~(1.5.53)~~



~~(1.5.54)~~

– wherein –

--"*" indicates the point of attachment of each said group of partial Formula (1.0.5) represented by partial Formulas (1.5.1), (1.5.3), (1.5.5) through (1.5.8), (1.5.10) through (1.5.12), (1.5.17 through (1.5.24), (1.5.26), (1.5.27 and (1.5.32) ~~through (1.5.54)~~ to the remaining portion of Formula (1.0.0).

5. (Canceled)

6. (Canceled)

7. (Currently amended) A compound according to Claim 1 wherein J' and the substituents R^4, R^5, and R^6 are selected in such a way that a portion of the left-hand terminus of a compound of Claim 1 is a member selected from the group consisting of partial Formulas

~~(2.0.1) through (2.0.72)~~ (2.0.11), (2.0.12), (2.0.14) - (2.0.20), (2.0.40), (2.0.60), (2.0.63) and (2.0.66) - (2.0.70):



~~(2.0.1)~~ ~~(2.0.2)~~ ~~(2.0.3)~~ ~~(2.0.4)~~



~~(2.0.5)~~ ~~(2.0.6)~~ ~~(2.0.7)~~ ~~(2.0.8)~~



~~(2.0.9)~~ ~~(2.0.10)~~ (2.0.11) (2.0.12)



~~(2.0.13)~~ (2.0.14) (2.0.15) (2.0.16)



(2.0.17) (2.0.18) (2.0.19) (2.0.20)



~~(2.0.21)~~ ~~(2.0.22)~~ ~~(2.0.23)~~ ~~(2.0.24)~~



~~(2.0.25)~~



~~(2.0.26)~~



~~(2.0.27)~~



~~(2.0.28)~~



~~(2.0.29)~~



~~(2.0.30)~~



~~(2.0.31)~~



~~(2.0.32)~~



~~(2.0.33)~~



~~(2.0.34)~~



~~(2.0.35)~~



~~(2.0.36)~~



~~(2.0.37)~~



~~(2.0.38)~~



~~(2.0.39)~~



(2.0.40)

~~(2.0.41)~~

~~(2.0.42)~~



~~(2.0.43)~~



~~(2.0.44)~~



~~(2.0.45)~~

~~(2.0.46)~~



~~(2.0.47)~~



~~(2.0.48)~~

~~(2.0.49)~~

~~(2.0.50)~~



~~(2.0.51)~~



~~(2.0.52)~~



~~(2.0.53)~~



~~(2.0.54)~~



~~(2.0.55)~~



~~(2.0.56)~~



~~(2.0.57)~~



~~(2.0.58)~~



~~(2.0.59)~~



(2.0.60)



~~(2.0.61)~~



~~(2.0.62)~~



(2.0.63)



~~(2.0.64)~~



~~(2.0.65)~~



(2.0.66)



(2.0.67)



(2.0.68)



(2.0.69)



(2.0.70)



~~(2.0.71)~~



~~(2.0.72)~~

8. (Canceled)

9. (Currently amended) A compound according to Claim 1 wherein J^2 and the substituents R^1 and R^2 are selected in such a way that a portion of the right-hand terminus of a compound of Claim 1 is a member selected from the group consisting of partial Formulas (2.5.1) to (2.5.7), (2.5.10), (2.5.14), (2.5.24) to (2.5.26), (2.5.34), (2.5.37 to (2.5.41) and ~~through~~ (2.5.50):



(2.5.1)



(2.5.2)



(2.5.3)



(2.5.4)









(2.5.5)



(2.5.6)



(2.5.7)



~~(2.5.8)~~



~~(2.5.9)~~



(2.5.10)



~~(2.5.11)~~



~~(2.5.12)~~



~~(2.5.13)~~



(2.5.14)



~~(2.5.15)~~

~~(2.5.16)~~

~~(2.5.17)~~

~~(2.5.18)~~

~~(2.5.19)~~



~~(2.5.20)~~



~~(2.5.21)~~



~~(2.5.22)~~



~~(2.5.23)~~



(2.5.24)



(2.5.25)



(2.5.26)



~~(2.5.27)~~



~~(2.5.28)~~

~~(2.5.29)~~

~~(2.5.30)~~



~~(2.5.31)~~



~~(2.5.32)~~



~~(2.5.33)~~



(2.5.34)



~~(2.5.35)~~



~~(2.5.36)~~



(2.5.37)



(2.5.38)



(2.5.39)



(2.5.40)





(2.5.41)



~~(2.5.42)~~



~~(2.5.43)~~



~~(2.5.44)~~



~~(2.5.45)~~



~~(2.5.46)~~



~~(2.5.47)~~



~~(2.5.48)~~



~~(2.5.49)~~



(2.5.50)

10. (Original) A compound according to Claim 1 wherein Y is $=C(R^1{}_a)-$ where $R^1{}_a$ is –H; -F; -Cl; $-CH_3$; or $-OCH_3$.

11. (Original) A compound according to Claim 10 wherein $R^1{}_a$ is –H; or -F.

12. (Currently amended) A compound according to Claim 1 wherein where m is 1 or 2, and n is 1; ◆ R^A and R^B are –H, $-CF_3$, or $-(C_1-C_6)$ alkyl substituted by 0 or 1 of –F, -Cl, $-CF_3$, –CN, $-NH_2$, or $-C(=O)NH_2$~~, or both taken together are spiro –(C$_3$-C$_6$) cycloalkyl– substituted by 0 or 1 of –F, -Cl, -CF$_3$, or –CN~~; ◆ one of R^C and R^D is -H, and the other is –H, $-(C_1-C_4)$ alkyl, or phenyl, each substituted by 0 or 1 of -F, -Cl, or –CN; ◆ W^1 is –O– or –S–; ◆ W^2 is –O–; ◆ Y is $= C(R^1{}_a)-$ where $R^1{}_a$ is -H, –F, –Cl, -CN, $-CH_3$, or $-OCH_3$; ◆ R^1 and R^2 are -H, –F, –Cl, –CN, $-NO_2$, -OH, $-CH_3$, $-OCH_3$, $-OCHF_2$, or $-OCF_3$; ◆ R^3 is -H or $-CH_3$; ◆ R^4 is –H, –F, –CN, $-NO_2$, -OH, $-CH_3$, or $-OCH_3$; ◆ J^1 is phenyl; ◆ R^5 and R^6 are taken together to form a moiety of partial Formula (1.3.1) where R^{20} and R^{21} are –H or $-CH_3$; or a moiety of partial Formula (1.3.11), (1.3.12), or (1.3.15) where R^{23} and R^{24} are absent or are –H, or $-CH_3$; ◆ J^2 is phenyl, norbornanyl~~, furanyl, thienyl, pyrimidinyl,~~ or cyclohexyl; ◆ and D is $-C(=O)OR^7$ where R^7 is -H or $-CH_3$; or $-C(=O)NH_2$~~; or tetrazol-5-yl~~.

13. (Currently amended) A compound according to Claim 12 wherein R^A and R^B are both $-CH_3$, or one is $-CH_3$ and the other is $-CH(CH_3)_2$ or $-C(CH_3)_3$, or one is –H and the other is $-CH_3$ or $-CF_3$~~, or both taken together are spiro-cyclopropyl or spiro-cyclobutyl~~; ◆ one of

R^C and R^D is –H and the other is –H or $–CH_3$; W^1 is –O–; ◆ Y is $=C(R^1{}_a)—$ where $R^1{}_a$ is –H, –F, or -Cl; ◆ R^1 and R^2 are –H, -F, or Cl; ◆ R^3 is –H; ◆ R^4 is –H; ◆ R^5 and R^6 are taken together to form a moiety of partial Formula (1.3.1) or (1.3.11) where R^{23} and R^{24} are both absent; ◆ J^2 is phenyl~~, thienyl,~~ or cyclohexyl; ◆ and D is -C(=O)OR^7 where R^7 is –H~~, or $–CH_3$~~; or $–C(=O)NH_2$~~; or tetrazol-5-yl~~.

14. (Currently amended) A compound according to Claim 13 wherein R^A and R^B are both ~~$–CH_3$, or both taken together are spiro-cyclopropyl~~; ◆ one of R^C and R^D is -H and the other is –H or $-CH_3$; ◆ Y is $=C(R^1{}_a)—$ where $R^1{}_a$ is –H, –F, or –Cl; ◆ R^1 and R^2 are –H, -F, or Cl; ◆ R^3 is -H; ◆ R^4 is –H; ◆ R^5 and R^6 are taken together to form a moiety of partial Formula (1.3.11) where R^{23} and R^{24} are both absent; ◆ J^2 is phenyl; ◆ and D is -C(=O)OR^7 where R^7 is –H or $–CH_3$; or $–C(=O)NH_2$~~; or tetrazol-5-yl~~.

15. (Original) A compound according to Claim 14 wherein R^A and R^B are both $–CH_3$; ◆ R^C and R^D are both –H; ◆ Y is $=C(R^1{}_a)—$ where $R^1{}_a$ is –H; ◆ and one of R^1 and R^2 is –H and the other is –F.

16. (Original) A compound according to Claim 14 wherein Y is $=C(R^1{}_a)—$ where $R^1{}_a$ is –F; ◆ and R^1 and R^2 are both –H.

17. (Currently amended) A compound according to Claim 13 wherein R^A and R^B are both ~~$–CH_3$, or both taken together are spiro-cyclopropyl~~; ◆ one of R^C and R^D is -H and the other is –H or $-CH_3$; ◆ Y is $=C(R^1{}_a)—$ where $R^1{}_a$ is –H, –F, or –Cl; ◆ R^1 and R^2 are –H, -F, or Cl; ◆ R^3 is -H; ◆ R^4 is –H; R^5 and R^6 are taken together to form a moiety of partial Formula (1.3.1) where R^{20} and R^{21} are both –H; ◆ J^2 is phenyl; ◆ and D is -C(=O)OR^7 where R^7 is –H or $–CH_3$; or $-C(=O)NH_2$~~; or tetrazol-5-yl~~.

18. (Original) A compound according to Claim 17 wherein R^A and R^B are both $–CH_3$; ◆ R^C and R^D are both –H; ◆ Y is $=C(R^1{}_a)—$ where $R^1{}_a$ is –H; ◆ and one of R^1 and R^2 is –H and the other is –F.

19. (Original) A compound according to Claim 18 wherein Y is $=C(R^1{}_a)—$ where $R^1{}_a$ is –F; ◆ and R^1 and R^2 are both –H.

20. (Currently amended) A compound according to Claim 1 wherein D is -P(=O)(OH)NHR^{25} ~~(substituted phosphoramido)~~; –S(=O)$_2$NHR^{26} or -NHS(=O)$_2$R^{26} ~~(sulfonamido)~~ where R^{26} is -CH$_3$, –CF$_3$, or *o*-toluyl; or -C(=O)NHS(=O)$_2$R^{25} ~~(acylsulfonamido); where R^{25} has the same meaning as defined in Claim 1~~.

21. (Currently amended) A compound according to Claim 1 wherein R^5 and R^6 ~~as~~ are taken together to form a moiety which is a member selected from the group consisting of partial Formulas (1.3.1), (1.3.11), (1.3.12), and (1.3.15):



(1.3.1)



(1.3.11)



(1.3.12)



(1.3.15)

~~where R^{20}, R^{21}, R^{23}, and R^{24} have the same meaning as defined in Claim 1~~.

22. (Original) A compound according to Claim 21 wherein R^5 and R^6 are taken together to form a moiety which is a member selected from the group consisting of partial Formulas (2.1.1), (2.1.4) through (2.1.6), (2.1.11), and (2.1.16) through (2.1.20):

(2.1.1)



(2.1.4)



(2.1.5)



(2.1.6)



(2.1.11)



(2.1.16)



(2.1.17)



(2.1.18)



(2.1.19)



(2.1.20)

wherein the dashed line – – – – in partial Formulas (2.1.18), (2.1.19), and (2.1.20) represents a double bond where no oxygen atom is attached to the corresponding nitrogen atom, and represents a single bond where an oxygen atom is attached to said corresponding nitrogen atom.

23. (Currently amended) A compound according to Claim 1 wherein the J^2 moiety is ~~cyclopentyl; cycloheptyl; cyclopentenyl;~~ cyclohexenyl~~; cycloheptenyl; norbornanyl; norbornenyl; bicyclo[2.2.2]octanyl; bicyclo[3.2.1]octanyl; bicyclo[3.3.0]octanyl; bicyclo[2.2.2]oct-5-enyl; bicyclo[2.2.2]oct-7-enyl; bicyclo[3.3.1]nonanyl; or adamantanyl~~.

24. (Canceled)

25. (Currently amended) A compound according to Claim 1 wherein said compound is a member selected from the group consisting of the following:

[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-acetic acid of Formula (5.5.1);

(±)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid of Formula (5.5.2);

(±)-2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid of Formula (5.5.3);

(±)-2-[3-Fluoro-4-({[2-(4-fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid of Formula (5.5.4);

(±)-2-[3-Fluoro-4-({[2-(3-cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid of Formula (5.5.5);

(±)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-5-fluoro-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid of Formula (5.5.6);

(±)-2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid of Formula (5.5.7);

(R)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid of Formula (5.5.8);

(S)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid of Formula (5.5.9);

(R)-2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid of Formula (5.5.10);

(R)-2-[3-Fluoro-4-({[2-(3-cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid of Formula (5.5.11);

(R)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-5-fluoro-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid of Formula (5.5.12);

(R)-2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid of Formula (5.5.13);

(R)-2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-(1-carbamoyl-ethoxy)-2-fluoro-benzyl]-nicotinamide of Formula (5.5.14);

(R)-2-(Benzo[2,1,3]oxadiazol-5-yloxy)-N-[4-(1-carbamoyl-ethoxy)-2-fluoro-benzyl]-nicotinamide of Formula (5.5.15);

(R)-2-(Benzo[2,1,3]thiadiazol-5-yloxy)-N-[4-(1-carbamoyl-ethoxy)-2-fluoro-benzyl]-nicotinamide of Formula (5.5.16);

(R)-N-[4-(1-Carbamoyl-ethoxy)-2-fluoro-benzyl]-2-(3-cyano-phenoxy)-nicotinamide of Formula (5.5.17);

(R)-2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-(1-carbamoyl-ethoxy)-2-fluoro-benzyl]-5-fluoro-nicotinamide of Formula (5.5.18);

~~(±)-2-(Benzo[1,3]dioxol-5-yloxy)-N-{2-fluoro-4-[1-(1H-tetrazol-5-yl)-ethoxy]-benzyl}-nicotinamide of Formula (5.5.19);~~

~~(R)-2-(Benzo[1,3]dioxol-5-yloxy)-N-{2-fluoro-4-[1-(5-methyl-4H-[1,2,4]triazol-3-yl)-ethoxy]-benzyl}-nicotinamide of Formula (5.5.20);~~

~~(R)-2-(Benzo[1,3]dioxol-5-yloxy)-5-fluoro-N-{2-fluoro-4-[1-(5-methyl-4H-[1,2,4]triazol-3-yl)-ethoxy]-benzyl}-nicotinamide of Formula (5.5.21);~~

~~(±)-2-(Benzo[1,3]dioxol-5-yloxy)-N-{2-fluoro-4-[1-(1H-tetrazol-5-yl)-ethoxy]-benzyl}-nicotinamide of Formula (5.5.22);~~

~~(R)-2-(Benzo[1,3]dioxol-5-yloxy)-N-[2-fluoro-4-(2-hydroxy-1,2-dimethyl-propoxy)-benzyl]-nicotinamide of Formula (5.5.23);~~

~~(R)-2-(Benzo[1,3]dioxol-5-yloxy)-5-fluoro-N-[2-fluoro-4-(2-hydroxy-1,2-dimethyl-propoxy)-benzyl]-nicotinamide of Formula (5.5.24);~~

~~(S)-3-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-2-methyl-propionic acid of Formula (5.5.25);~~

~~2-(Benzo[1,3]dioxol-5-yloxy)-5-fluoro-N-[2-fluoro-4-(pyridin-2-ylmethoxy)-benzyl]-nicotinamide of Formula (5.5.26);~~

~~2-(Benzo[1,3]dioxol-5-yloxy)-5-fluoro-N-[2-fluoro-4-(pyridin-4-ylmethoxy)-benzyl]-nicotinamide of Formula (5.5.27);~~

~~2-(Benzo[1,3]dioxol-5-yloxy)-5-fluoro-N-[2-fluoro-4-(pyridin-3-ylmethoxy)-benzyl]-nicotinamide of Formula (5.5.28);~~

[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid of Formula (5.5.29);

[4-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid of Formula (5.5.30);

(±)-2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.31);

(±)-2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.32);

(±)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.33);

(±)-2-[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.34);

(±)-2-[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.35);

(±)-2-[4-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.36);

(R)-2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.37);

(R)-2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.38);

(R)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.39);

(R)-2-[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.40);

(R)-2-[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.41);

(R)-2-[4-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-propionic acid of Formula (5.5.42);

[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-acetic acid of Formula (5.5.43);

[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-acetic acid of Formula (5.5.44);

[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-acetic acid of Formula (5.5.45);

[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-acetic acid of Formula (5.5.46);

[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-acetic acid of Formula (5.5.47);

[4-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-acetic acid of Formula (5.5.48);

(±)-2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.49);

(±)-2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.50);

(±)-2-[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.); of Formula (5.5.51);

(±)-2-[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.52);

(±)-2-[4-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.53);

(R)-2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.54);

(R)-2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.55);

(R)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.56);

(R)-2-[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.57);

(R)-2-[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.58);

(R)-2-[4-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.59);

2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-2-methyl-propionic acid of Formula (5.5.60);

2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-2-methyl-propionic acid of Formula (5.5.61);

2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-2-methyl-propionic acid of Formula (5.5.62);

2-[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-2-methyl-propionic acid of Formula (5.5.63);

2-[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-2-methyl-propionic acid of Formula (5.5.64);

2-Methyl-2-[4-({[2-(2-methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohexyloxy]-propionic acid of Formula (5.5.65);

~~[5-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-bicyclo[2.2.2]oct-2-yloxy]-acetic acid of Formula (5.5.66);~~

~~(±)-2-[5-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-bicyclo[2.2.2]oct-2-yloxy]-propionic acid of Formula (5.5.67);~~

~~(R)-2-[5-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-bicyclo[2.2.2]oct-2-yloxy]-propionic acid of Formula (5.5.68);~~

~~2-[5-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-bicyclo[2.2.2]oct-2-yloxy]-2-methyl-propionic acid of Formula (5.5.69);~~

~~2-[5-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-bicyclo[2.2.2]oct-2-yloxy]-2-methyl-propionic acid of Formula (5.5.70);~~

~~(R)-2-[5-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-bicyclo[2.2.2]oct-2-yloxy]-propionic acid of Formula (5.5.71);~~

~~[5-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-bicyclo[2.2.2]oct-2-yloxy]-acetic acid of Formula (5.5.72);~~

~~2-[8-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-bicyclo[2.2.2]oct-5-en-2-yloxy]-2-methyl-propionic acid of Formula (5.5.73);~~

~~(R)-2-[3-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-bicyclo[3.2.1]oct-8-yloxy]-propionic acid of Formula (5.5.74);~~

~~2-[3-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclopent-3-enyloxy]-propionic acid of Formula (5.5.75);~~

~~5-({[2-(2-Methyl-2H-benzotriazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-bicyclo[2.2.1]hept-2-yloxy]-acetic acid of Formula (5.5.76);~~

~~2-[5-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-7-fluoro-bicyclo[2.2.1]hept-5-en-2-yloxy]-2-methyl-propionic acid of Formula (5.5.77);~~

~~(R)-2-[5-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-furan-2-yloxy]-propionic acid of Formula (5.5.78);~~

~~(±)-2-[6-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-pyridin-3-yloxy]-propionic acid of Formula (5.5.79);~~

~~[2-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-oxazol-5-yloxy]-acetic acid of Formula (5.5.80);~~

~~2-[2-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-thiazol-5-yloxy]-2-methyl-propionic acid of Formula (5.5.81);~~

~~(±)-2-[5-(1-{[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-ethyl)-pyridin-2-yloxy]-propionic acid of Formula (5.5.82);~~

2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-2-methyl-propionic acid of Formula (5.5.83);

2-[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-2-methyl-propionic acid of Formula (5.5.84);

2-[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-2-methyl-propionic acid of Formula (5.5.85);

2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-2-methyl-propionic acid of Formula (5.5.86);

2-[3-Fluoro-4-({[2-(4-fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-2-methyl-propionic acid of Formula (5.5.87);

2-[4-({[2-(3-Cyano-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-2-methyl-propionic acid of Formula (5.5.88);

[4-({[2-(Benzo[2,1,3]thiadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid of Formula (5.5.89);

~~(±)-2-(3-Cyano-phenoxy)-N-{4-[1-(5-methyl-4H-[1,2,4]triazol-3-yl)-ethoxy]-cyclohexylmethyl}-nicotinamide of Formula (5.5.90);~~

~~(±)-2-(3-Cyano-phenoxy)-N-{4-[1-(1H-tetrazol-5-yl)-ethoxy]-cyclohexylmethyl}-nicotinamide of Formula (5.5.91);~~

~~(±)-N-{2-Fluoro-4-[1-(5-methyl-4H-[1,2,4]triazol-3-yl)-ethoxy]-benzyl}-2-(3-methoxy-phenoxy)-nicotinamide of Formula (5.5.92);~~

~~N-[2-Fluoro-4-(pyridin-2-ylmethoxy)-benzyl]-2-(3-methoxy-phenoxy)-nicotinamide of Formula (5.5.93);~~

(±)-2-[3-Fluoro-4-({[2-(3-nitro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid of Formula (5.5.94);

~~(±)-N-{2-Fluoro-4-[1-(1H-tetrazol-5-yl)-ethoxy]-benzyl}-2-(3-nitro-phenoxy)-nicotinamide of Formula (5.5.95);~~

~~(±)-N-{2-Fluoro-4-[1-(5-methyl-4H-[1,2,4]triazol-3-yl)-ethoxy]-benzyl}-2-(3-nitro-phenoxy)-nicotinamide of Formula (5.5.96);~~

[4-({[2-(Benzo[2,1,3]oxadiazol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid of Formula (5.5.97);

[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid of Formula (5.5.98);

[4-({[2-(4-Fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-cyclohex-3-enyloxy]-acetic acid of Formula (5.5.99);

(R)-2-[4-({[2-(3-Methoxy-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid of Formula (5.5.100);

(R)-2-[3-Fluoro-4-({[2-(3-methoxy-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid of Formula (5.5.101);

(R)-2-[3-Fluoro-4-({[5-fluoro-2-(3-methoxy-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid of Formula (5.5.102);

(R)-2-[4-({[2-(3-Nitro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid of Formula (5.5.103);

(R)-2-[4-({[2-(3-Chloro-4-fluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid of Formula (5.5.104);

(R)-2-[4-({[2-(3,4-Difluoro-phenoxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid of Formula (5.5.105);

(R)-2-[4-({[2-(2,3-Dihydro-benzofuran-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid of Formula (5.5.106); and

(R)-2-[4-({[2-(2,3-Dihydro-benzofuran-6-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-phenoxy]-propionic acid of Formula (5.5.107);

~~(S)-2-(Benzo[1,3]dioxol-5-yloxy)-N-{2-fluoro-4-[1-(1H-tetrazol-5-yl)-ethoxy]-benzyl}-nicotinamide of Formula (5.5.108);~~

~~(R)-2-(Benzo[1,3]dioxol-5-yloxy)-N-{2-fluoro-4-[1-(1H-tetrazol-5-yl)-ethoxy]-benzyl}-nicotinamide of Formula (5.5.109);~~

~~(R)-3-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-2-methyl-propionic acid of Formula (5.5.110);~~

~~(S)-2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-(2-carbamoyl-propoxy)-2-fluoro-benzyl]-nicotinamide of Formula (5.5.111);~~

~~(R)-2-(Benzo[1,3]dioxol-5-yloxy)-5-fluoro-N-{2-fluoro-4-[1-(1H-tetrazol-5-yl)-ethoxy]-benzyl}-nicotinamide of Formula (5.5.112);~~

~~(±)-2-(3-Methoxy-phenoxy)-N-{4-[1-(1H-tetrazol-5-yl)-ethoxy]-benzyl}-nicotinamide of Formula (5.5.113);~~

~~2-[5-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-thiophen-2-yloxy]-propionic acid of Formula (5.5.114); and~~

~~(±)-2-(Benzo[1,3]dioxol-5-yloxy)-*N*-{2-fluoro-4-[1-methyl-2-oxo-2-(4*H*-[1,2,4]triazol-3-yl)-ethoxy]-benzyl}-nicotinamide of Formula (5.5.115).~~

26. - 30. (Canceled)

Add new claims 31 - 40:

31. (New) A method of treating a disease, disorder or condition mediated by the PDE4 isozyme in a mammal, said method comprising administering to said mammal in need of such mediation, a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

32. (New) A method of claim 31 wherein said PDE4 isozyme is the PDE4-D subtype isozyme.

33. (New) A method of claim 31 wherein said disease, disorder or condition is atopic asthma; non-atopic asthma; allergic asthma; bronchial asthma; essential asthma; true asthma; intrinsic asthma caused by pathophysiologic disturbances; extrinsic asthma caused by environmental factors; essential asthma of unknown or inapparent cause; bronchitic asthma; emphysematous asthma; exercise-induced asthma; occupational asthma; infective asthma caused by bacterial, fungal, protozoal or viral infection; non-allergic asthma; incipient asthma; or wheezy infant syndrome.

34. (New) A method of claim 31 wherein said disease, disorder or condition is chronic or acute bronchoconstriction; chronic bronchitis; small airways obstruction; emphysema; pneumoconiosis; chronic eosinophilic pneumonia; chronic obstructive pulmonary disease; adult respiratory distress syndrome; or exacerbation of airways hyper-reactivity consequent to other drug therapy.

35. (New) A method of claim 34 wherein said chronic obstructive pulmonary disease is characterized by irreversible, progressive airways obstruction.

36. (New) A method of claim 34 wherein said pneumonconiosis is aluminosis; bauxite workers' disease; anthracosis; miners' disease; asbestosis; steam-fitters' asthma; chalicosis; flint disease; ptilosis caused by inhaling the dust from ostrich feathers; siderosis caused by the inhalation of iron particles; silicosis; grinders' disease; byssinosis; cotton-dust asthma; or talc pneumoconiosis.

37. (New) A method of claim 31 wherein said disease, disorder or condition is bronchitis; acute bronchitis; chronic bronchitis; acute laryngotracheal bronchitis; arachidic bronchitis; catarrhal bronchitis; croupus bronchitis; dry bronchitis; infectious asthmatic bronchitis; productive bronchitis; staphylococcus bronchitis; streptococcal bronchitis; or vesicular bronchitis.

38. (New) A method of claim 31 wherein said disease, disorder or condition is bronchiectasis; cylindric bronchiectasis; sacculated bronchiectasis; fusiform brochiectasis; capillary bronchiectasis; cystic bronchiectasis; dry bronchiectasis or follicular bronchiectasis.

39. (New) A method of claim 31 wherein said disease, disorder or condition is seasonal allergic rhinitis; perennial allergic rhinitis; sinusitis; purulent sinusitis; nonpurulent sinusitis; acute sinusitis; chronic sinusitis; ethmoid sinusitis; frontal sinusitis; or sphenoid sinusitis.

40. (New) A method of claim 31 wherein said disease, disorder or condition is regulated by the activation and degranulation of eosinophils.

41. (New) A compound of claim 1 which is (R)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid.